TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03331081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder Training
Description: The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
Study: NCT00518141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid and Terbutalin
Description: ASA 75 mg, Terbutalin 5mg
Study: NCT03331081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMAP
Description: There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
Study: NCT04492774

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Goldic serum
Description: epidural injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injections
Description: epidural injections

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Veno-lymphatic drainage
Study: NCT03674489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic Slider Mobilization
Description: Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULNT2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to slide the nerve proximally and distally in an alternating manner via providing wrist extension with concurrent shoulder girdle elevation and then providing wrist flexion with concurrent shoulder girdle depression. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance.
Study: NCT03331081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Training + TMAP
Description: Will perform the exercises of the bladder training group and the TMAP in an associated way.
Study: NCT04186273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrosis-Inhibiting-Compound-FS2
Description: There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrosis-Inhibiting-Compound-FS2
Description: There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrosis-Inhibiting-Compound-FS2
Description: There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrosis-Inhibiting-Compound-FS2
Description: There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle moisture balancing base
Description: Vehicle base without FS2.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle moisture balancing base
Description: Vehicle base without FS2.
Study: NCT00754923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
Study: NCT04736433

Intervention type: DRUG
Intervention: ACE inhibitor
Description: ACE inhibitor dispensing claim is used as the reference
Study: NCT00518141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid and Terbutalin
Description: ASA 75 mg, Terbutalin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid and Terbutalin
Description: ASA 75 mg, Terbutalin 5mg
Study: NCT05733806

Intervention type: OTHER
Intervention: chemotherapy, surgery
Description: this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
Study: NCT01597661

Intervention type: DRUG
Intervention: Exposure to any bupropion during the first trimester
Description: The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves.

Intervention type: DRUG
Intervention: Exposure to bupropion alone during the first trimester
Description: The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves.

Intervention type: OTHER
Intervention: Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy
Description: The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves.
Study: NCT01933347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
Study: NCT03674489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic Tensioner Mobilization
Description: Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULND2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to tension the nerve in an alternating on/off manner via providing wrist extension with concurrent shoulder girdle depression and then providing wrist flexion with concurrent shoulder girdle elevation. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance.
Study: NCT04736433

Intervention type: DRUG
Intervention: Sacubitril/Valsartan
Description: Sacubitril/Valsartan dispensing claim is used as the reference
Study: NCT04329455

Intervention type: PROCEDURE
Intervention: Endoscopic thyroidectomy
Description: Endoscopic thyroidectomy in Thyroid Nodules
Study: NCT03674489

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Neurodynamic Mobilization
Description: Subjects will be positioned in supine with the examiner supporting his/her arm and facing cranially - in a similar position as the UNLD1 test described previously. From here, the therapist will position the patient's arm in 45 deg. of shoulder abduction without scapular depression, 45 deg. of shoulder external rotation, 45 deg. of elbow flexion, and forearm pronation. From this position, a series of sham mobilizations will be performed by passively alternating flexion and extension of the wrist for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position).
Study: NCT00807794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.012 mg/kg dose given twice between 60 to 72 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.06 mg/kg dose given twice between 60 to 72 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.12 mg/kg dose given twice between 60 to 72 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
Study: NCT02422264

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: • All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: • All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: • All subjects will receive Infanrix hexa co-administered with Prevenar13\* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. \*In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevnar13
Description: • All subjects will receive Infanrix hexa co-administered with Prevenar13\* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. \*In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
Study: NCT02059863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPRING
Description: SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
Study: NCT03105453

Intervention type: OTHER
Intervention: 3 Sampling points
Description: When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
Study: NCT01502254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: audio recorded information
Description: Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
Study: NCT02686411

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT01842204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic field therapy device
Description: Therapy device for 1 week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non magnetic field therapy device.
Description: Non-active device for 1 week.
Study: NCT02538523

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia FX-635
Description: The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
Study: NCT02874677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effort reeducation program
Description: personalized reeducation program at a load level preceding hyperventilation
Study: NCT06576479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritious Shake
Description: Powder 70 g/d diluted in 237 ml natural water

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional counseling
Description: Specialized nutritional recommendations for CKD
Study: NCT01731496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone reminder
Description: One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
Study: NCT03968601

Intervention type: OTHER
Intervention: Mitral regurgitation surgery such as mitral valve replacement or repair
Description: Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
Study: NCT01702987

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ubiquinol
Description: ubiquinol supplementation was given for 1 month to 12 patients
Study: NCT01731496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message reminder
Description: One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
Study: NCT01702987

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: statin
Description: statin was given for 1 month to 21 patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin
Description: statin was given for 1 month to 21 patients
Study: NCT00335348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
Study: NCT03187158

Intervention type: DIAGNOSTIC_TEST
Intervention: Forced Oscillation Technique
Description: F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Forced Oscillation Technique
Description: F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
Study: NCT02130518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auriclosene Irrigation Solution, 0.2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Auriclosene Vehicle Solution
Study: NCT01922180

Intervention type: RADIATION
Intervention: Chest CT scans
Description: CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
Study: NCT00616408

Intervention type: DRUG
Intervention: Octreotide-LAR
Description: Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
Study: NCT03848286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167 Injection
Description: KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Study: NCT05612867

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin C
Description: Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin C
Description: Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
Study: NCT00561834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
Study: NCT02216747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone 60 mg/meter square Body Surface Area
Description: treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
Study: NCT03016858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic Bullectomy Surgery
Description: undergoing the Thoracoscopic Bullectomy Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic Bullectomy Surgery
Description: undergoing the Thoracoscopic Bullectomy Surgery
Study: NCT01980823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: (Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
Study: NCT03142568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.